<DOC>
	<DOCNO>NCT00003653</DOCNO>
	<brief_summary>RATIONALE : Androgens stimulate growth prostate cancer cell . Hormone therapy may fight prostate cancer reduce production androgen . It yet know androgen suppression regimen effective prostate cancer . PURPOSE : This randomized phase III trial study two hormone therapy regimens compare see well work treat patient rise PSA level follow radiation therapy prostate cancer .</brief_summary>
	<brief_title>Hormone Therapy Treating Patients With Rising PSA Levels Following Radiation Therapy Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival prostate cancer patient prostate-specific antigen progression clinical absence distant metastases prior radical radiotherapy treat intermittent androgen suppression ( IAS ) vs continuous androgen deprivation ( CAD ) . - Compare time development hormone resistance patient treat regimen . - Compare quality life patient treat regimen . - Compare serum cholesterol HDL/LDL level 3 year baseline compare annually patient treat regimen . - Evaluate duration treatment non-treatment interval , time testosterone recovery ( return pre-therapy level ) , time recover potency patient treat IAS . OUTLINE : This randomize , multicenter study . Patients stratify accord prior radical prostatectomy ( yes v ) , time since completion prior radical radiotherapy ( 1 3 year vs 3 year ) , baseline prostate-specific antigen ( PSA ) value ( 3-15 ng/mL v great 15 ng/mL ) , prior hormonal therapy ( neo-adjuvant , concurrent , adjuvant cytoreduction association radical radiotherapy treatment prostatectomy maximum duration 12 month complete least 12 month prior randomization ) ( yes v ) . Patients randomize one two treatment arm . - Arm I : Patients undergo intermittent androgen suppression ( IAS ) . Patients receive luteinizing hormone-releasing hormone ( LHRH ) analog ( buserelin [ BSRL ] , goserelin [ ZDX ] , leuprolide [ LEUP ] ) antiandrogen ( nilutamide [ ANAN ] , flutamide [ FLUT ] , bicalutamide [ CDX ] , cyproterone acetate [ CPTR ] ) 8 month . Patients receive LHRH analog subcutaneous ( SC ) intramuscular ( IM ) implant every 1-4 month begin within 5 day randomization oral antiandrogen 1-3 time daily , depend actual LHRH analog antiandrogen . PSA level monitor every 2 month . If PSA fall normal 8-month treatment period , therapy stop level rise 10 ng/mL , time IAS resume another 8-month period . IAS continue long PSA level control . At time disease progression , patient begin continuous hormonal treatment similar arm II . - Arm II : Patients undergo continuous androgen deprivation without scheduled interruption . Patients receive LHRH analog ( BSRL , ZDX , LEUP ) antiandrogen ( ANAN , FLUT , CDX , CPTR ) OR undergo bilateral orchiectomy within 5 day randomization receive antiandrogen . Patients receive LHRH analog SC IM implant every 1-4 month begin within 5 day randomization oral antiandrogen 1-3 time daily , depend actual LHRH analog antiandrogen . PSA level monitor every 2 month . Treatment continue hormone resistance develops . Patients receive LHRH analog may begin antiandrogen therapy either prior simultaneously LHRH analog must continue antiandrogen therapy least 4 week block tumor flare . Quality life assess randomization , every 4 month 2 year , every 8 month development hormone resistance , time hormone resistance , annually thereafter . Patients follow annually survival . PROJECTED ACCRUAL : A total 1,386 patient accrue study within 7 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Buserelin</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Nilutamide</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven adenocarcinoma prostate prior initiation radiotherapy Prior pelvic radiotherapy prostate cancer , either postradical prostatectomy primary management More 30 month since prior brachytherapy curative intent Prostatespecific antigen must rise great 3 ng/mL high low level record previously since end radiotherapy ( i.e. , high postradiotherapy nadir ) Total testosterone great 5 nmol/L No definite evidence metastatic disease Chest xray bone scan negative metastasis Radiological change compatible nonmalignant disease allow Clinical evidence local disease allow PATIENT CHARACTERISTICS : Age : 16 ( 18 participate center United Kingdom ) Performance status : ECOG 01 Life expectancy : More 5 year Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST/ALT great 1.5 time ULN LDH great 1.5 time ULN No chronic liver disease Renal : Creatinine great 1.5 time ULN Other : Sufficiently fluent willing complete quality life questionnaire either English French Fertile patient must use effective contraception No malignancy within past 5 year except curatively treat basal squamous cell skin cancer superficial bladder cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No prior concurrent biologic therapy Chemotherapy : No prior concurrent chemotherapy Endocrine therapy : Prior hormonal therapy administer prior , , immediately radical radiotherapy prostatectomy allow provided duration longer 12 month At least 12 month since prior hormonal therapy Radiotherapy : See Disease Characteristics At least 12 month since prior radiotherapy No concurrent palliative radiotherapy Surgery : See Disease Characteristics See Endocrine therapy Other : No concurrent bisphosphonates</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>